|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
21
|
|
pubmed:dateCreated |
2003-11-5
|
|
pubmed:abstractText |
Long-term tamoxifen treatment of breast cancer can result in tamoxifen-stimulated breast cancer, in which estrogen inhibits tumor growth after tamoxifen withdrawal. We investigated the molecular mechanism(s) of estradiol-induced tumor regression by using an in vivo model of tamoxifen-stimulated human breast cancer.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Hormonal,
http://linkedlifedata.com/resource/pubmed/chemical/Estradiol,
http://linkedlifedata.com/resource/pubmed/chemical/Estrogen Receptor Modulators,
http://linkedlifedata.com/resource/pubmed/chemical/FASLG protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Fas Ligand Protein,
http://linkedlifedata.com/resource/pubmed/chemical/Fasl protein, mouse,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Glycoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/Tamoxifen,
http://linkedlifedata.com/resource/pubmed/chemical/Transforming Growth Factor alpha,
http://linkedlifedata.com/resource/pubmed/chemical/fulvestrant
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1460-2105
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
5
|
|
pubmed:volume |
95
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1597-608
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:14600092-Animals,
pubmed-meshheading:14600092-Antineoplastic Agents, Hormonal,
pubmed-meshheading:14600092-Blotting, Western,
pubmed-meshheading:14600092-Breast Neoplasms,
pubmed-meshheading:14600092-Estradiol,
pubmed-meshheading:14600092-Estrogen Receptor Modulators,
pubmed-meshheading:14600092-Fas Ligand Protein,
pubmed-meshheading:14600092-Female,
pubmed-meshheading:14600092-Humans,
pubmed-meshheading:14600092-In Situ Nick-End Labeling,
pubmed-meshheading:14600092-Membrane Glycoproteins,
pubmed-meshheading:14600092-Mice,
pubmed-meshheading:14600092-Mice, Nude,
pubmed-meshheading:14600092-Polymerase Chain Reaction,
pubmed-meshheading:14600092-Receptor, erbB-2,
pubmed-meshheading:14600092-Tamoxifen,
pubmed-meshheading:14600092-Transforming Growth Factor alpha,
pubmed-meshheading:14600092-Transplantation, Heterologous
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer.
|
|
pubmed:affiliation |
Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
